Clinical Trials
140 trialsTherapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
University of Nebraska
HER3+
Cancer Insight, LLC
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Eastern Cooperative Oncology Group
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Institutes of Health Clinical Center (CC)
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Cancer Insight, LLC
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
Vaccine Therapy in Treating Patients With Breast Cancer
San Antonio Military Medical Center
GIPI
Northern California Melanoma Center
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Barbara Ann Karmanos Cancer Institute
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
University of Washington
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Roswell Park Cancer Institute
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Maryland, Baltimore
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
University of California, San Francisco
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
Oncology Specialists, S.C.
Neoadjuvant Treatment of Breast Cancer
University of California, Irvine
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
CML0206
Gruppo Italiano Malattie EMatologiche dell'Adulto
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
Montefiore Medical Center
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
University of California, Irvine
ACT III
Celldex Therapeutics
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
M.D. Anderson Cancer Center